Midgard Science

Axcelead

Kanagawa, Japan axcelead-us.com From their website, Nov 2026

Work here? Claim this listing

About

Axcelead Drug Discovery Partners, Inc. provides drug discovery and development services for biotechnology and pharmaceutical partners, with work spanning target discovery through IND enabling. It is based in Fujisawa, Kanagawa, Japan and was formed in 2017 as a Takeda spin-out.

Services

  • Integrated drug discovery

    End-to-end drug discovery services from target discovery to IND-enabling translational research.

  • Axcelead Booster

    Data-driven drug candidate generation using legacy pharma projects, proprietary data, AI tools, and discovery platforms.

  • Target identification / validation

    Supports identification of novel drug targets using human data-driven transcriptomics and proteomics, and validates targets with human samples and disease models.

  • Hit identification / characterization

    Provides HTS strategy design, assay development, hit characterization, compound library screening, and hit prioritization.

  • Lead generation / optimization

    Supports medicinal and analytical chemistry, biology, DMPK, safety evaluation, and in silico design for lead generation and optimization.

  • Candidate selection

    Evaluates optimized compounds for IND feasibility using PK/PD/E, TK/TD, modeling and simulation, human PK/effective dose prediction, and safety assessment.

    ADME, DMPK & toxicology

  • IND enabling

    Provides Smart-IND project support from candidate selection to IND filing, including strategy, project management, non-GMP bulk preparation, and modality-specific planning.

    ADME, DMPK & toxicology

  • Chemistry

    Offers medicinal, computational, synthetic, and analytical chemistry, including hit expansion, lead generation, and lead optimization.

6 more services
  • Targeted protein degradation
  • RNA-targeted small molecules
  • Omics
  • Bioinformatics
  • In Vitro/In Vivo Pharmacology
  • Genetically Modified Animal
Lead time
  • 2 days to 12 months
  • 1 year
What to send
  • Diseases of interest, target classes, or specific targets
  • Organization / Company

Capabilities

Processes
  • Small molecule
  • Peptide
  • Oligonucleotide
  • Cell therapy
  • HTS
  • In vivo
Capacity
  • 1.2+ million compounds
  • 1,000 pharma-originated legacy projects
  • 700+ HTS experiences
  • 96 parallel syntheses over 5 to 10 days
  • More than 50 projects for 5 years
  • 7 candidates
3 more
  • 1 IND
  • About 240 employees
  • 1.5 million compounds

Equipment

  • High throughput screening
  • GPU machines
  • 2000 CPU cluster machines

Industries served

  • Biotech
  • Pharmaceuticals
  • Academia
  • Public institutions

Company

Type
CRO
Founded
2017
Team
About 240

Locations

Based in
Kanagawa, Japan
Sites
  • Fujisawa, Japan
  • Fujisawa, Kanagawa, Japan
Serves
Biotechnology and pharmaceutical partners, corporate, start-up, academia, and public institutions, Japan, around the world

Similar labs